Enspryng

(satralizumab)
1 ML satralizumab-mwge 120 MG/ML Prefilled Syringe [Enspryng]
NO BLACK BOX WARNING

Dosage & administration

Most viewed Enspryng resources

Enroll in Patient Savings Program

drug label

Enspryng prescribing information

Have more Enspryng questions?

Submit MSL Request
Learn More

Need to report an Enspryng issue?

ONLINE FORM
Report adverse event
Learn More

prior authorization

Enspryng Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRAND
Coverage Authorization Request
Coverage Authorization Appeals
Learn More

Benefits investigation

Enspryng Start Form
Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRAND
Reimbursement help (FRM) resources
Learn More

financial assistance

Enspryng Financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program
Enspryng Start Form
Learn More

Bridge program

commercial only
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Genentech Patient Assistance Program Application - Online, Prescriber Form
Genentech Patient Assistance Program Application - PDF, Prescriber Form
Learn More

patient education

Enspryng Patient education

Getting started on Enspryng

Instructions For Use - Neuromyelitis Optica Spectrum Disorder (NMOSD)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient toolkit

About Enspryng
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Enspryng FAQs

Is there a pregnancy exposure registry for ENSPRYNG?Yes, there is a pregnancy exposure registry for ENSPRYNG that monitors pregnancy outcomes in women exposed to the drug during pregnancy. Healthcare providers are encouraged to register patients, and pregnant women are encouraged to register themselves by calling 1-833-277-9338.
What is the risk of using ENSPRYNG during pregnancy?There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
Is satralizumab-mwge present in human milk?No information is available on the presence of satralizumab-mwge in human milk. Satralizumab-mwge was excreted in the milk of lactating monkeys administered satralizumab-mwge throughout pregnancy. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ENSPRYNG and any potential adverse effects on the breastfed infant from ENSPRYNG or from the underlying maternal condition.
Is ENSPRYNG safe and effective for use in pediatric patients?Safety and effectiveness in pediatric patients have not been established.
Are there any specific considerations for dosing ENSPRYNG in elderly patients?Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.
FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.